{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:05:56Z","timestamp":1760385956458},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1668","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Etranacogene dezaparvovec-drlb (Hemgenix \u2013 CSL Behring), an adeno-associated virus vector-based gene therapy, has been approved by the FDA for treatment of hemophilia B in adults who currently receive factor IX prophylaxis therapy or have had life-threatening or repeated, serious, spontaneous bleeding episodes.<\/jats:p>","DOI":"10.58347\/tml.2023.1668a","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T21:03:41Z","timestamp":1676408621000},"page":"9-10","source":"Crossref","is-referenced-by-count":7,"title":["Hemgenix - A Gene Therapy for Hemophilia B"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,1,23]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T21:03:46Z","timestamp":1676408626000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1668a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":0,"journal-issue":{"issue":"1668","published-online":{"date-parts":[[2023,1,23]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1668a","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]}}}